-25.0%
QXO vs MRNA
+945.0%
-970.0%
-62.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +8.1% | +13.1% | -5.0% | +7.3% |
| 7D | +16.6% | +20.6% | -4.1% | +15.3% |
| 30D | +6.6% | +27.1% | -20.6% | +4.7% |
| 3M | -17.5% | +353.4% | -370.8% | -29.5% |
| 6M | -33.8% | +446.3% | -480.0% | -48.0% |
| YTD | -34.4% | +776.2% | -810.5% | -56.4% |
| 1Y | -25.0% | +987.9% | -1,012.9% | -55.9% |
| All | -25.0% | +945.0% | -970.0% | -55.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling